Pain
Conditions
Keywords
Palliative, Osteopathy
Brief summary
The culture of the palliative is anchored more and more in France. In 2009, nearly 9 out of 10 French people (89%) believe that palliative care can reduce the suffering of people at the end of their lives. Despite the rise of palliative care in France, their access is not homogeneous between regions. In 2010, it is estimated that 2 French out of 3 likely to receive palliative care could not access it. Palliative care remains essential at the end of the patient's life, as well as for the family and caregivers. The French government has put in place three national palliative care development programs: 2002-2005, 2008-2012, 2015-2018. The last program has unlocked a budget of 190 million euros for their development. It has been estimated from Social Security reimbursements, that the costs per patient over their last years of life are 26,000 euros, for a total of 13.5 million euros. One of the most important aspects of palliative care is the comfort of the patients as well as their feelings in the care. In order to best meet the expectations of cancer patients, some offer early palliative care that is effective in improving both the quality of life of the patient and its life expectancy. Osteopathy is a manual alternative medicine whose goal is to restore the lack of mobility of tissues. It can be used as a complementary treatment when a specific support is put in place. The purpose of this study is to examine the effectiveness of osteopathy in the reduction of pain in adult patients in palliative care.
Interventions
OTHERQuestionnaire and treatment
EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
Sponsors
Centre Hospitalier Intercommunal Creteil
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major patient (age\> 18) male or female * Patient hospitalized or admitted to a day hospital that can be followed * EVA between 40/100 and 60/100 * Signed informed consent
Exclusion criteria
* Patients requiring a modification of analgesic molecule during the study. * Clinical stability of the patient estimated during the duration of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VAS (Visual Analog Scale) evaluation (0 to 100) | day 6 | Evolution of the score of the Visual Analogue Scale (VAAS) on 100 between D0 and D6 and D0 and D1, D0 and D2, D0 and D3, D0 and D4, D0 and D5 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dose of analgesic (g) | day 6 | Variation of the analgesic intake between D0 and D6 and D0 and D1, J1 and D2, J2 and D3, D3 and D4, D4 and D5, D5 and D6. |
| QLQ (Quality of life questionnaire) C15 Pal score | days 6 | Variation of the quality of life questionnaire (QLQ) C15 Pal score between D0 and D6 |
Countries
France
Outcome results
None listed